Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines - PACE-CME

Rationale for the lower LDLc targets in the ESCEAS Dyslipidemia Guidelines

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
Betablocker use associated with reduced mortality in HFrEF patients >80 years
Betablocker use associated with reduced mortality in HFrEF patients >80 years
ESC 2019
Betablocker use associated with reduced mortality in HFrEF patients >80 years
- Gianluigi Savarese, MD
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
ESC 2019
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
- Prof. Freek Verheugt